Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Amortization of Deferred Charges (2022 - 2025)

Historic Amortization of Deferred Charges for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Q3 2025 value amounting to $59000.0.

  • Orchestra BioMed Holdings' Amortization of Deferred Charges changed N/A to $59000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $154000.0, marking a year-over-year change of. This contributed to the annual value of $31000.0 for FY2024, which is 7232.14% down from last year.
  • Latest data reveals that Orchestra BioMed Holdings reported Amortization of Deferred Charges of $59000.0 as of Q3 2025.
  • Over the past 5 years, Orchestra BioMed Holdings' Amortization of Deferred Charges peaked at $59000.0 during Q3 2025, and registered a low of $3000.0 during Q4 2023.
  • For the 3-year period, Orchestra BioMed Holdings' Amortization of Deferred Charges averaged around $38727.3, with its median value being $36000.0 (2022).
  • Within the past 5 years, the most significant YoY rise in Orchestra BioMed Holdings' Amortization of Deferred Charges was 277.78% (2023), while the steepest drop was 9166.67% (2023).
  • Quarter analysis of 3 years shows Orchestra BioMed Holdings' Amortization of Deferred Charges stood at $36000.0 in 2022, then tumbled by 91.67% to $3000.0 in 2023, then skyrocketed by 1866.67% to $59000.0 in 2025.
  • Its Amortization of Deferred Charges was $59000.0 in Q3 2025, compared to $46000.0 in Q2 2025 and $46000.0 in Q1 2025.